Dr. Helen Ma, MD
Claim this profileTibor Rubin VA Medical Center
Studies Lymphoma
Studies Leukemia
3 reported clinical trials
9 drugs studied
Area of expertise
1Lymphoma
13q positive
13q negative
12 positive
2Leukemia
13q positive
13q negative
12 positive
Affiliated Hospitals
Clinical Trials Helen Ma, MD is currently running
Oral Azacitidine + R-miniCHOP
for Diffuse Large B-Cell Lymphoma
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone [R-miniCHOP]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Recruiting1 award Phase 2 & 314 criteria
Azacytidine + Romidepsin
for Peripheral T-Cell Lymphoma
This trial is testing if a combination of two drugs, romidepsin and azacytidine, is safe and effective for patients with aggressive Peripheral T-Cell Lymphoma that hasn't responded to other treatments. The goal is to see if this combination works better than using just one drug alone. Romidepsin is approved for certain types of T-cell lymphoma and has shown positive results in various T-cell cancers.
Recruiting1 award Phase 211 criteria
More about Helen Ma, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Helen Ma, MD has experience with
- Venetoclax
- Obinutuzumab
- Oral Azacitidine
- Rituximab
- Cyclophosphamide
- Prednisone
Breakdown of trials Helen Ma, MD has run
Lymphoma
Lymphoid Leukemia
Chronic B-Cell Leukemia
Chronic Lymphocytic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Helen Ma, MD specialize in?
Helen Ma, MD focuses on Lymphoma and Leukemia. In particular, much of their work with Lymphoma has involved 13q positive patients, or patients who are 13q negative.
Is Helen Ma, MD currently recruiting for clinical trials?
Yes, Helen Ma, MD is currently recruiting for 3 clinical trials in Long Beach California. If you're interested in participating, you should apply.
Are there any treatments that Helen Ma, MD has studied deeply?
Yes, Helen Ma, MD has studied treatments such as Venetoclax, Obinutuzumab, Oral Azacitidine.
What is the best way to schedule an appointment with Helen Ma, MD?
Apply for one of the trials that Helen Ma, MD is conducting.
What is the office address of Helen Ma, MD?
The office of Helen Ma, MD is located at: Tibor Rubin VA Medical Center, Long Beach, California 90822 United States. This is the address for their practice at the Tibor Rubin VA Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.